These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34370872)

  • 21. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
    Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
    J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
    Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
    J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
    [No Abstract]   [Full Text] [Related]  

  • 23. Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria.
    Magen E
    Acta Derm Venereol; 2019 Sep; 99(10):919-920. PubMed ID: 31233178
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical and laboratory parameters associated with treatment response to third-line therapies in chronic refractory urticaria: A real world study from northern India.
    Mehta H; Bishnoi A; Parsad D; Kumaran MS
    Dermatol Ther; 2022 Nov; 35(11):e15887. PubMed ID: 36181400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis.
    Karstarli Bakay OS; Kacar N
    Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106
    [No Abstract]   [Full Text] [Related]  

  • 26. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria.
    Maurer M; Kolkhir P; Moñino-Romero S; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668
    [No Abstract]   [Full Text] [Related]  

  • 27. Real-world dosing of omalizumab for chronic spontaneous urticaria.
    McIntyre AP; Viswanathan RK; Moss MH; Mathur SK
    Ann Allergy Asthma Immunol; 2020 Feb; 124(2):211-212. PubMed ID: 31805358
    [No Abstract]   [Full Text] [Related]  

  • 28. Omalizumab re-treatment rates in chronic spontaneous urticaria.
    Khan S; Sholtysek S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397
    [No Abstract]   [Full Text] [Related]  

  • 29. Real world evidence on treatment of chronic spontaneous urticaria with omalizumab: Preliminary data.
    Corrao S; Prestigiacomo MA; Angileri RG; Natoli G; Argano C
    Dermatol Ther; 2020 Jul; 33(4):e13458. PubMed ID: 32319167
    [No Abstract]   [Full Text] [Related]  

  • 30. Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab.
    Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
    Clin Exp Allergy; 2021 Dec; 51(12):1648-1652. PubMed ID: 34519110
    [No Abstract]   [Full Text] [Related]  

  • 31. Plasma adenosine is linked to disease activity and response to treatment in patients with chronic spontaneous urticaria.
    Mao M; Liu H; Yan S; Yuan Y; Liu R; Wu Y; Peng C; Li J; Chen X
    Allergy; 2021 Feb; 76(2):571-573. PubMed ID: 32687639
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.
    Passante M; Napolitano M; Dastoli S; Bennardo L; Fabbrocini G; Nisticò SP; Patruno C
    Dermatol Ther; 2021 Nov; 34(6):e15111. PubMed ID: 34427028
    [No Abstract]   [Full Text] [Related]  

  • 33. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.
    Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P
    Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841
    [No Abstract]   [Full Text] [Related]  

  • 34. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience.
    Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A
    An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series.
    Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
    He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
    Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic spontaneous urticaria refractory to cyclosporine add-on omalizumab successfully treated with methotrexate add-on.
    Garbayo-Salmons P; Expósito-Serrano V
    Dermatol Ther; 2020 Nov; 33(6):e14469. PubMed ID: 33112010
    [No Abstract]   [Full Text] [Related]  

  • 38. Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy.
    Liao SL; Yu M; Zhao ZT; Maurer M
    Front Immunol; 2021; 12():652973. PubMed ID: 33796115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic inducible urticaria a particular form of chronic urticaria.
    Soria A
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):452-453. PubMed ID: 38391218
    [No Abstract]   [Full Text] [Related]  

  • 40. Children with chronic spontaneous urticaria: Recurrence after remission and its predictors.
    Özyılmaz-Bozat G; Şahiner ÜM; Buyuktiryaki B; Uysal-Soyer Ö; Şekerel BE
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):796-798.e1. PubMed ID: 31425834
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.